AstraZeneca announced that Cambridge City Council has granted planning permission for the company’s new global research and development center and corporate headquarters in the city. The facility will be located on the Cambridge Biomedical Campus and will be home to approximately 2,000 employees.
“We are very pleased with…[the] decision by Cambridge City Council. Work is underway to prepare the site on the Cambridge Biomedical Campus and we look forward to beginning construction in the spring. Our aim is to create an open, welcoming and vibrant center that will inspire our teams and partners to push the boundaries of scientific innovation for the benefit of patients,” says Mene Pangalos, Executive Vice President, Innovative Medicines & Early Development at AstraZeneca.
The Cambridge site will bring together AstraZeneca’s small molecule and biologics research and development activity. It will become the company’s largest center for oncology research, as well as housing scientists focused on cardiovascular and metabolic diseases, respiratory, inflammation and autoimmune diseases and conditions of the central nervous system. A joint research center also will be housed there, which will see Medical Research Council-supported researchers working side-by-side with AstraZeneca’s high throughput screening group.